Rationale for the potential use of calcitonin in osteoarthritis.
This review provides evidence that osteoarthritis (OA) or a major subset of OA is not only a disease of cartilage but also a disorder of subchondral bone. This review also discusses the potential efficacy of a bone and cartilage active agent, calcitonin, and discusses how calcitonin might be useful in the pharmaceutical treatment of OA.
Manicourt
D H
DH
Department of Rheumatology, University Hospital St Luc, Universite Catholique de Louvain, Brussels, Belgium.
Devogelaer
J P
JP
Azria
M
M
Silverman
S
S
D050071:Bone Density Conservation Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016723:Bone Remodeling / Q000187:drug effects / Q000502:physiology; D001842:Bone and Bones / Q000187:drug effects* / Q000503:physiopathology; D002116:Calcitonin / Q000494:pharmacology* / Q000627:therapeutic use; D002358:Cartilage, Articular / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D007596:Joints / Q000378:metabolism / Q000502:physiology / Q000503:physiopathology; D010003:Osteoarthritis / Q000188:drug therapy* / Q000503:physiopathology; D013314:Stress, Mechanical; D016474:Weight-Bearing / Q000502:physiology
D050071:Bone Density Conservation Agents; D002116:Calcitonin